Skandinaviska Enskilda Banken AB publ increased its position in Thermo Fisher Scientific Inc (NYSE:TMO) by 1.5% during the first quarter, Holdings Channel reports. The institutional investor owned 63,315 shares of the medical research company’s stock after buying an additional 930 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Thermo Fisher Scientific were worth $9,725,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Independent Portfolio Consultants Inc. boosted its position in Thermo Fisher Scientific by 0.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 730 shares of the medical research company’s stock valued at $112,000 after buying an additional 2 shares during the period. Sharkey Howes & Javer boosted its position in Thermo Fisher Scientific by 1.0% in the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock valued at $113,000 after buying an additional 7 shares during the period. Washington Trust Bank boosted its position in Thermo Fisher Scientific by 0.5% in the first quarter. Washington Trust Bank now owns 2,210 shares of the medical research company’s stock valued at $339,000 after buying an additional 10 shares during the period. Beacon Trust Co. boosted its position in Thermo Fisher Scientific by 0.6% in the first quarter. Beacon Trust Co. now owns 2,159 shares of the medical research company’s stock valued at $341,000 after buying an additional 12 shares during the period. Finally, Dumont & Blake Investment Advisors LLC boosted its position in Thermo Fisher Scientific by 0.3% in the first quarter. Dumont & Blake Investment Advisors LLC now owns 5,526 shares of the medical research company’s stock valued at $849,000 after buying an additional 15 shares during the period. 87.60% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Thermo Fisher Scientific Inc (TMO) traded up 1.19% on Wednesday, reaching $175.63. The company’s stock had a trading volume of 487,001 shares. Thermo Fisher Scientific Inc has a 1-year low of $139.07 and a 1-year high of $182.87. The company’s 50 day moving average is $176.78 and its 200-day moving average is $166.23. The firm has a market cap of $68.52 billion, a price-to-earnings ratio of 30.60 and a beta of 1.06.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The company had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.92 billion. During the same period last year, the firm posted $2.03 earnings per share. The business’s revenue was up 10.2% on a year-over-year basis. Equities research analysts expect that Thermo Fisher Scientific Inc will post $9.24 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Stockholders of record on Friday, September 15th will be given a $0.15 dividend. The ex-dividend date is Thursday, September 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.35%. Thermo Fisher Scientific’s payout ratio is 10.45%.

COPYRIGHT VIOLATION WARNING: This article was first posted by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/08/16/skandinaviska-enskilda-banken-ab-publ-has-9-73-million-stake-in-thermo-fisher-scientific-inc-tmo.html.

Several equities analysts have weighed in on the company. Bank of America Corporation lifted their target price on Thermo Fisher Scientific from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday, May 9th. Cleveland Research raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research note on Thursday, July 20th. Jefferies Group LLC lifted their target price on Thermo Fisher Scientific from $160.00 to $175.00 and gave the company a “hold” rating in a research note on Friday, April 28th. BidaskClub cut Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 27th. Finally, Citigroup Inc. reaffirmed a “buy” rating and set a $201.00 target price (up previously from $182.00) on shares of Thermo Fisher Scientific in a research note on Monday, July 10th. One equities research analyst has rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Thermo Fisher Scientific presently has a consensus rating of “Buy” and a consensus target price of $188.56.

In related news, CFO Stephen Williamson sold 2,500 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $176.26, for a total transaction of $440,650.00. Following the completion of the sale, the chief financial officer now directly owns 37,790 shares of the company’s stock, valued at approximately $6,660,865.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 20,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $172.79, for a total value of $3,455,800.00. Following the sale, the chief executive officer now directly owns 269,279 shares of the company’s stock, valued at $46,528,718.41. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 27,188 shares of company stock valued at $4,702,223. Insiders own 0.49% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.